ColorTime

ColorTime is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation chimeric antigen receptor T-cell (CAR-T) therapies. The company focuses on overcoming the limitations of current cell therapies, such as high costs and limited efficacy in solid tumors, through its proprietary 'Super CAR-T' and 'Universal CAR-T' platforms. Their pipeline includes candidates targeting CD19 and CD20 for hematological malignancies, as well as novel targets for solid tumors like ovarian cancer. ColorTime's technology aims to enhance T-cell persistence and potency, potentially offering superior clinical outcomes. The company is backed by prominent venture capital firms and is actively advancing multiple programs through clinical trials in China.